Sugi Predict

Sugi Predict / Compounds / SCHEMBL712388

SCHEMBL712388

SCHEMBL712388

CC[C@H](C)[C@H](N)C(=O)OCC[C@@H](CO)Cn1cnc2c(=O)[nH]c(N)nc21

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MEN1 O00255 2/20 0.59
▸ KMT2A Q03164 2/20 0.59
▸ HBB P68871 2/20 0.58
▸ MAPK1 P28482 1/20 0.58
▸ PDE3A Q14432 1/20 0.56
▸ HPRT1 P00492 11/20 0.50
▸ BLM P54132 2/20 0.50
▸ ALDH1A1 P00352 1/20 0.50
▸ LMNA P02545 1/20 0.50
▸ CYP3A4 P08684 1/20 0.50
▸ NFKB1 P19838 1/20 0.50
▸ VCP P55072 1/20 0.50
▸ SMN1; SMN2 Q16637 1/20 0.50
▸ HIF1A Q16665 1/20 0.50
▸ PNP P00491 2/20 0.49
▸ USP2 O75604 1/20 0.49
▸ TSHR P16473 1/20 0.49
▸ EDNRA P25101 1/20 0.49
▸ HTR2A P28223 1/20 0.49
▸ RECQL P46063 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3699745 1.00 MEN1 (0.59) MEN1KMT2AHBBMAPK1PDE3A
SCHEMBL712389 1.00 MEN1 (0.59) MEN1KMT2AHBBMAPK1PDE3A
SCHEMBL711073 0.93 MEN1 (0.59) MEN1KMT2AHBBMAPK1PDE3A
SCHEMBL711071 0.93 MEN1 (0.59) MEN1KMT2AHBBMAPK1PDE3A
SCHEMBL711072 0.93 MEN1 (0.59) MEN1KMT2AHBBMAPK1PDE3A
Valomaciclovir SCHEMBL711293 0.92 MEN1 (0.70) MEN1KMT2AHBBMAPK1PDE3A
Valomaciclovir SCHEMBL417653 0.92 MEN1 (0.70) MEN1KMT2AHBBMAPK1PDE3A
SCHEMBL708716 0.88 MEN1 (0.54) MEN1KMT2AHBBMAPK1PDE3A
SCHEMBL708717 0.88 MEN1 (0.54) MEN1KMT2AHBBMAPK1PDE3A
SCHEMBL708715 0.88 MEN1 (0.54) MEN1KMT2AHBBMAPK1PDE3A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120123119-A1 ACYCLIC NUCLEOSIDE DERIVATIVES MEDIVIR AB (SE) 2012-05-17 — — US disclosed
US-8124609-B2 Acyclic nucleoside derivatives MEDIVIR AB (SE) 2012-02-28 — — US disclosed
US-20090076041-A1 ACYCLIC NUCLEOSIDE DERIVATIVES MEDIVIR AB (SE) 2009-03-19 — — US disclosed
US-7432274-B2 Acyclic nucleoside derivatives MEDIVIR AB (SE) 2008-10-07 — — US disclosed
US-7189849-B2 Synthesis of acyclic nucleoside derivatives MEDIVIR AB (SE) 2007-03-13 — — US disclosed
US-20050250795-A1 Synthesis of acyclic nucleoside derivatives MEDIVIR AB (SE) 2005-11-10 — — US disclosed
US-6878844-B2 Synthesis of acyclic nucleoside derivatives MEDIVIR AB (SE) 2005-04-12 — — US disclosed
US-20040248910-A1 Synthesis of acyclic nucleoside derivatives MEDIVIR AB (SE) 2004-12-09 — — US disclosed
US-20040132749-A1 Acyclic nucleoside derivatives MEDIVIR AB (SE) 2004-07-08 — — US disclosed
US-6703394-B2 VIRICIDES SUCH AS (R)-9-(2-(STEAROYLOXYMETHYL)-4-(L-VALYLOXY) BUTYL)GUANINE FOR TREATMENT OF HIV; BIOAVAILABILITY MEDIVIR AB (SE) 2004-03-09 — — US disclosed
EP-0880521-B1 SYNTHESIS OF ACYCLIC NUCLEOSIDES MEDIVIR AB (SE) 2003-01-22 — — EP disclosed
EP-0888348-B1 ACYCLIC NUCLEOSIDE DERIVATIVES MEDIVIR AB (SE) 2003-01-22 — — EP disclosed
US-20020188125-A1 Acyclic nucleoside derivatives MEDIVIR AB 2002-12-12 — — US disclosed
US-6255312-B1 VIRICIDES MEDIVIR AB (SE) 2001-07-03 — — US disclosed
US-6184376-B1 POTENT ANTIVIRALS, ESPECIALLY AGAINST HERPES INFECTIONS, SUCH AS THOSE CAUSED BY VARICELLA ZOSTER VIRUS, HERPES SIMPLEX, EPSTEIN-BARR VIRUS, HERPES TYPE 6 (HHV-6) AND TYPE 8 (HHV-8). SHINGLES IN THE ELDERLY OR CHICKEN POX IN THE YOUNG MEDIVER AB (SE) 2001-02-06 — — US disclosed
US-5869493-A ANTIVIRALS AGAINST HERPES AND RETROVIRUSES MEDIVIR AB (SE) 1999-02-09 — — US disclosed
EP-0888348-A1 ACYCLIC NUCLEOSIDE DERIVATIVES Medivir Aktiebolag (SE) 1999-01-07 — — EP disclosed
EP-0880521-A1 SYNTHESIS OF ACYCLIC NUCLEOSIDES Medivir Aktiebolag (SE) 1998-12-02 — — EP disclosed
WO-1997030052-A1 SYNTHESIS OF ACYCLIC NUCLEOSIDES MEDIVIR AB (SE) 1997-08-21 — — WO disclosed
WO-1997030051-A1 ACYCLIC NUCLEOSIDE DERIVATIVES MEDIVIR AB (SE) 1997-08-21 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090076041-A1 ACYCLIC NUCLEOSIDE DERIVATIVES NUDT1, PNP, NSUN2 MEN1 1917/4885KMT2A 2396/4885HBB 1470/4885
US-20120123119-A1 ACYCLIC NUCLEOSIDE DERIVATIVES NUDT1, PNP, NSUN2 MEN1 1895/4885KMT2A 2400/4885HBB 1507/4885
US-20040132749-A1 Acyclic nucleoside derivatives NSUN2, NUDT1, PNP MEN1 2312/4885KMT2A 2483/4885HBB 1773/4885
US-20040248910-A1 Synthesis of acyclic nucleoside derivatives NSUN2, SLC28A1, NUDT1 MEN1 1883/4885KMT2A 2577/4885HBB 2205/4885
US-20050250795-A1 Synthesis of acyclic nucleoside derivatives ASNS, NUDT1, PNP MEN1 1376/4885KMT2A 2608/4885HBB 2182/4885
US-20020188125-A1 Acyclic nucleoside derivatives NSUN2, NUDT1, PNP MEN1 2510/4885KMT2A 2354/4885HBB 1623/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.